this says the most to me. i want to look in previous reports how they word it, but sounds like a shift in their modus operandi. from 'cochlear therapies' to 'innovative treatments in neurotology rhinology allergy and cns disorders'
this is a consolidation of their efforts towards the most profitable paths - tinnitus has huge potential but those royalties are harsh to INSERM & Xigen..
betahistine has always looked to hold the most secure financial potential, with bentrio as a nice covid-shaped cherry on top. we golden, boys..